A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function.
about
Evaluation and management of patients with heart disease and cancer: cardio-oncologyIntra-myocardial injection of both growth factors and heart derived Sca-1+/CD31- cells attenuates post-MI LV remodeling more than does cell transplantation alone: neither intervention enhances functionally significant cardiomyocyte regenerationRegulation of Long Bone Growth in Vertebrates; It Is Time to Catch UpAngiotensin-converting enzyme 2 is an essential regulator of heart functionHypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau proteinCardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heartMouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequencesOxygen, oxidative stress, hypoxia, and heart failure.Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction.Association of myocardial angiogenesis with structural and functional ventricular remodeling in aortic stenosis patients with normal ejection fractionMutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor.Systemic maternal inflammation and neonatal hyperoxia induces remodeling and left ventricular dysfunction in miceVEGF signaling has distinct spatiotemporal roles during heart valve development.NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis.Sirtuin 1 ablation in endothelial cells is associated with impaired angiogenesis and diastolic dysfunction.Hypoxia and fetal heart development.The endothelium-dependent effect of RTEF-1 in pressure overload cardiac hypertrophy: role of VEGF-BThe sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis.Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophyMicroRNA-20a constrains p300-driven myocardial angiogenic transcription by direct targeting of p300.Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overloadA story of two ACEs.VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart.Gli3 regulation of myogenesis is necessary for ischemia-induced angiogenesisPlacental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism.Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice.VEGF-C and aortic cardiomyocytes guide coronary artery stem development.The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial InfarctionBiomaterial based cardiac tissue engineering and its applicationsAngiotensinII preconditioning promotes angiogenesis in vitro via ERKs phosphorylationLong Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in MiceCardiac angiogenic imbalance leads to peripartum cardiomyopathy.C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heartComparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Placental growth factor as a protective paracrine effector in the heart
P2860
Q26998273-62DA07E2-C668-40FF-9DDD-1B860F19D103Q27338187-5974C411-5E73-421D-AB04-E021BB8CBE9EQ28083996-6524C317-BA59-4E5B-8807-42A2BA64D174Q28205840-0B79ADCF-3BA3-4D5A-B7BB-A8048088AB2DQ28269238-94422460-48E6-4021-BEAB-96BAF06EBBC5Q28509556-4F3B3C16-3D7C-41E2-AA66-5C88D77274E8Q30481126-C0AAE285-4701-485C-AFF1-9412E516E631Q30847302-D7C37FF8-4CF7-4CFF-B7CB-2C24C0F0D107Q33408049-F1305273-1E93-4B78-9DD7-57651E75C90FQ33428551-7081E184-D655-40BC-9183-0246C5EB1016Q33683779-78DD7915-5C91-40E7-B4AF-E023D55230D0Q33777861-D783734F-2982-4948-B84F-54A49D173AB0Q33896306-4E7F18F9-A59F-4083-87D2-389F5FAC5A2AQ33999797-854202FB-7925-47A9-8B39-FBCD48FE4174Q34026152-55B62E6E-2F62-4645-934B-5902073843DBQ34216642-435D259C-EA22-48A4-A329-6657B177F051Q34241578-253536E9-973D-4C4B-BC41-9BA495D4E8E7Q34726894-67B525A9-AF82-4D0F-A5B1-C0326CE629ACQ34788585-57AE6EBB-1CBC-4CA7-BC13-46B41C6EC670Q34808450-743E89F9-8029-46BD-A20F-1C02AC88CF4CQ34999372-43E39526-28A6-459D-89E9-3CC17EE203E0Q35003522-201280F7-3645-4646-89AA-37BACD0ECF91Q35043713-67F886A3-7F64-425A-8AF2-0927D771A33CQ35095396-1D486E26-6C30-4979-B97E-A561616E264AQ35109747-1150AAB6-4E1C-4B46-8365-42E639588071Q35114758-8097E458-BF10-494C-A584-B8E53FBD667CQ35117261-FEAB724F-0DF3-4A34-8D8D-40BBBA209FE2Q35135394-2E76CF70-540D-4DB0-A024-76BFF829FA59Q35135731-73FD26CD-F0D1-4962-8A74-0B782B0E2460Q35140087-E09B6D0B-D28F-4ADF-878C-D5D2200A0668Q35354723-ABCB9F95-2F62-4419-9BD3-587D47716600Q35694608-965ECB72-F049-4F6F-AB2D-C415E9DA94E1Q35731251-FF065788-A99C-49BB-941E-2263872CC74FQ35830097-BDF7F520-FD86-4B68-B09C-7B4AB1473D55Q35937588-4B05C7CE-7DAF-452A-96CF-DDE72B33C8F9Q35975055-9158A80B-D297-4B0A-8292-3902DE934B4AQ36080823-BCEFF1FD-2714-4D7A-A15E-95FF83288F56Q36138509-9A642321-D679-4A04-9328-F178A28721D8Q36163040-5A45D044-1DBB-44CD-B399-0BF444AA6B32Q36180150-90A2BDC8-2D5F-49D2-8BBE-88669ED1D446
P2860
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
A cardiac myocyte vascular end ...... to maintain cardiac function.
@ast
A cardiac myocyte vascular end ...... to maintain cardiac function.
@en
type
label
A cardiac myocyte vascular end ...... to maintain cardiac function.
@ast
A cardiac myocyte vascular end ...... to maintain cardiac function.
@en
prefLabel
A cardiac myocyte vascular end ...... to maintain cardiac function.
@ast
A cardiac myocyte vascular end ...... to maintain cardiac function.
@en
P2093
P2860
P356
P1476
A cardiac myocyte vascular end ...... to maintain cardiac function.
@en
P2093
Giordano FJ
P2860
P304
P356
10.1073/PNAS.091415198
P407
P577
2001-05-01T00:00:00Z